Core Viewpoint - The company has developed an upgraded 20-valent pneumococcal conjugate vaccine based on the existing 13-valent vaccine, which has received approval for clinical trials from the National Medical Products Administration [1][4]. Group 1: Vaccine Development - The new 20-valent pneumococcal conjugate vaccine includes 7 additional serotypes, covering a total of 20 serotypes that are currently prevalent, aimed at preventing invasive diseases such as pneumonia, meningitis, and bacteremia [3]. - The vaccine is intended for administration to individuals aged 2 months and older, targeting infections caused by the 20 serotypes included in the vaccine [3]. Group 2: Public Health Significance - Pneumococcal diseases are a significant global public health issue, being a major cause of morbidity and mortality among children and adults in China [2]. - The World Health Organization (WHO) classifies pneumococcal diseases as requiring "extremely high priority" for vaccine prevention, highlighting the urgent need for effective vaccination strategies [2]. Group 3: Market Position and Future Plans - The approval of the 20-valent vaccine for clinical trials enhances the company's pipeline in the pneumococcal vaccine sector, indicating a commitment to addressing unmet clinical needs in core disease areas [4]. - The company aims to continue advancing innovative vaccine development to improve its innovation capabilities, core competitiveness, and overall strength in the market [4].

Core Viewpoint - The company has developed an upgraded 20-valent pneumococcal conjugate vaccine based on the existing 13-valent vaccine, which has received approval for clinical trials from the National Medical Products Administration [1][4]. Group 1: Vaccine Development - The new 20-valent pneumococcal conjugate vaccine includes 7 additional serotypes, covering a total of 20 serotypes that are currently prevalent, aimed at preventing invasive diseases such as pneumonia, meningitis, and bacteremia [3]. - The vaccine is intended for administration to individuals aged 2 months and older, targeting infections caused by the 20 serotypes included in the vaccine [3]. Group 2: Public Health Significance - Pneumococcal diseases are a significant global public health issue, being a major cause of morbidity and mortality among children and adults in China [2]. - The World Health Organization (WHO) classifies pneumococcal diseases as requiring "extremely high priority" for vaccine prevention, highlighting the urgent need for effective vaccination strategies [2]. Group 3: Market Position and Future Plans - The approval of the 20-valent vaccine for clinical trials enhances the company's pipeline in the pneumococcal vaccine sector, indicating a commitment to addressing unmet clinical needs in core disease areas [4]. - The company aims to continue advancing innovative vaccine development to improve its innovation capabilities, core competitiveness, and overall strength in the market [4].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的 任 何 損 失 承 擔 任 何 責 任。 – 1 – 全 部 位 於 非 洲 和 亞 洲，佔 全 球 總 病 例 數 的66%，而 中 國 位 列 第 二，佔 全 球 總病例數的12%。WHO對 可 用 疫 苗 預 防 的 疾 病 的 分 級 中，將 肺 炎 球 菌 性 疾 病 定 為 需「極 高 度 優 先」使 用 疫 苗 預 防 的 疾 病。 AIM Vaccine Co., Ltd. 艾美疫苗股份有限公司 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） （股 份 代 號：06660） 自願性公告 20價肺炎球菌多糖結合疫苗 獲批開展臨床試驗 本 公 告 由 艾 美 疫 苗 股 份 有 限 公 司（「本公司」，連 同 其 附 屬 公 司 統 稱「本 集 團」）自 願 作 出，以 告 知 本 公 司 股 東 及 潛 在 投 資 者 本 集 團 ...